Skip to main content
Fig. 2 | Journal of Hematology & Oncology

Fig. 2

From: CDK7 inhibitor THZ1 enhances antiPD-1 therapy efficacy via the p38α/MYC/PD-L1 signaling in non-small cell lung cancer

Fig. 2

CDK7 inhibitor THZ1 promotes apoptosis and suppresses NSCLC growth in vitro and in vivo. a CCK8 assay depicting the changes in the viability of A549, H460, and SKMES1 cells treated with different doses of THZ1 for time points as indicated (n = 3). b Representative images showing colony formation of A549 and H460 cells treated with vehicle or THZ1. c Representative images of annexin V/propidium iodide staining showing increased apoptosis in NSCLC cells treated with THZ1. d Quantification of the annexin V positive cell ratio (n = 3) (***P < 0.001 as compared to vehicle group). e Representative images showing increased TUNEL positive cells (with nucleus stained in red) after THZ1 treatment at 48 h (× 40 magnification). f Quantification of the TUNEL positive cell ratio (n = 3) (***P < 0.001 as compared to vehicle group). g Caspase-3 activity was measured after NSCLC cells were treated with THZ1 (200 nM) for 48 h. Results are presented as fold-increase to vehicle-treated samples (n = 3) (*** P < 0.001). h Tumor growth curves of a lung adenocarcinoma PDX model treated with either vehicle or THZ1. Data represent mean ± SD (n = 6) (P = 0.0036). i Tumor growth curves of the H460 xenograft model treated with either vehicle or THZ1. Data represent mean ± SD (n = 8) (P < 0.0001). j H&E and IHC staining of Ki67 and cleaved caspase-3 in tumor tissue sections from H460 xenograft. Original magnification, × 400; scale bar, 20 μm

Back to article page